Delivery of Orally Administered Digestible Antibodies Using Nanoparticles.

Published on Mar 25, 2021in International Journal of Molecular Sciences4.556
· DOI :10.3390/IJMS22073349
Sources
Abstract
Oral administration of medications is highly preferred in healthcare owing to its simplicity and convenience; however, problems of drug membrane permeability can arise with any administration method in drug discovery and development. In particular, commonly used monoclonal antibody (mAb) drugs are directly injected through intravenous or subcutaneous routes across physical barriers such as the cell membrane, including the epithelium and endothelium. However, intravenous administration has disadvantages such as pain, discomfort, and stress. Oral administration is an ideal route for mAbs. Nonetheless, proteolysis and denaturation, in addition to membrane impermeability, pose serious challenges in delivering peroral mAbs to the systemic circulation, biologically, through enzymatic and acidic blocks and, physically, through the small intestinal epithelium barrier. A number of clinical trials have been performed using oral mAbs for the local treatment of gastrointestinal diseases, some of which have adopted capsules or tablets as formulations. Surprisingly, no oral mAbs have been approved clinically. An enteric nanodelivery system can protect cargos from proteolysis and denaturation. Moreover, mAb cargos released in the small intestine may be delivered to the systemic circulation across the intestinal epithelium through receptor-mediated transcytosis. Oral Abs in milk are transported by neonatal Fc receptors to the systemic circulation in neonates. Thus, well-designed approaches can establish oral mAb delivery. In this review, I will introduce the implementation and possibility of delivering orally administered mAbs with or without nanoparticles not only to the local gastrointestinal tract but also to the systemic circulation.
References53
Newest
2 CitationsSource
The humoral immune response provides specific, long-lived protection against invading pathogens, via immunoglobulin production and other memory functions. IgG, the most abundant immunoglobulin isotype, has the longest half-life and protects against bacterial and viral infections. The neonatal Fc receptor (FcRn) transports IgG across barriers, for example, the placenta, enhancing fetal humoral immunity to levels similar to their mothers'. Importantly, FcRn, by protecting IgG from intracellular de...
8 CitationsSource
#1Kim Y. Green (NIH: National Institutes of Health)H-Index: 58
#2Stuart S. Kaufman (GUMC: Georgetown University Medical Center)H-Index: 3
Last. Stanislav V. Sosnovtsev (NIH: National Institutes of Health)H-Index: 34
view all 17 authors...
Human noroviruses are a major cause of diarrheal illness, but pathogenesis is poorly understood. Here, we investigate the cellular tropism of norovirus in specimens from four immunocompromised patients. Abundant norovirus antigen and RNA are detected throughout the small intestinal tract in jejunal and ileal tissue from one pediatric intestinal transplant recipient with severe gastroenteritis. Negative-sense viral RNA, a marker of active viral replication, is found predominantly in intestinal ep...
14 CitationsSource
#1Yousif H-E. Y. Ibrahim (Omdurman Islamic University)H-Index: 1
#2Géza Regdon (University of Szeged)H-Index: 13
Last. Tamás Sovány (University of Szeged)H-Index: 8
view all 4 authors...
Objectives The main objective of present review is to explore and evaluate the effectiveness of recently developed methods to improve the bioavailability of orally administered biopharmaceutical drugs.
15 CitationsSource
#1Susan Hua (University of Newcastle)H-Index: 20
: The oral route is by far the most common route of drug administration in the gastrointestinal tract and can be used for both systemic drug delivery and for treating local gastrointestinal diseases. It is the most preferred route by patients, due to its advantages, such as ease of use, non-invasiveness, and convenience for self-administration. Formulations can also be designed to enhance drug delivery to specific regions in the upper or lower gastrointestinal tract. Despite the clear advantages...
13 CitationsSource
#1Zhenhua Hu (Houston Methodist Hospital)H-Index: 8
#2Sara Nizzero (Houston Methodist Hospital)H-Index: 7
Last. Haifa Shen (Cornell University)H-Index: 38
view all 8 authors...
Low oral bioavailability of peptide drugs has limited their application to parenteral administration, which suffers from poor patient compliance. Here, we show that molecular targeting of the FATP4 transporter is an effective approach to specifically transport long-chain fatty acid (LCFA)–conjugated peptides across the enterocytic membrane and, thus, enables oral delivery of drug peptides. We packaged LCFA-conjugated exendin-4 (LCFA-Ex4) into liposomes and coated with chitosan nanoparticles to f...
5 CitationsSource
: Discriminatory drug delivery into target cells is essential to effectively elicit the drug activity and to avoid off-target side effects; however, transporting drugs across the cell membrane is difficult due to factors such as molecular size, hydrophilicity, intercellular adhesiveness, and efflux transporters, particularly, in the brain capillary endothelial cells. Drug delivery into the brain is blocked by the blood-brain barrier (BBB). Thus, developing drugs for the central nervous system (C...
6 CitationsSource
#1Yutaka Nakamura (UTokyo: University of Tokyo)H-Index: 7
#2Hitomi Mimuro (UTokyo: University of Tokyo)H-Index: 36
Last. Koji Hase (UTokyo: University of Tokyo)H-Index: 44
view all 9 authors...
Infectious colitis is one of the most common health issues worldwide. Microfold (M) cells actively transport luminal antigens to gut-associated lymphoid tissue to induce IgA responses; however, it remains unknown whether M cells contribute to the induction of cellular immune responses. Here we report that M cell-dependent antigen transport plays a critical role in the induction of Th1, Th17, and Th22 responses against gut commensals in the steady state. The establishment of commensal-specific ce...
5 CitationsSource
#1Kosuke Murakami (BCM: Baylor College of Medicine)H-Index: 14
#2Victoria R. Tenge (BCM: Baylor College of Medicine)H-Index: 9
Last. Mary K. Estes (BCM: Baylor College of Medicine)H-Index: 94
view all 15 authors...
Human noroviruses (HuNoVs) cause sporadic and epidemic outbreaks of gastroenteritis in all age groups worldwide. We previously reported that stem cell-derived human intestinal enteroid (HIE) cultures support replication of multiple HuNoV strains and that some strains (e.g., GII.3) replicate only in the presence of bile. Heat- and trypsin-treatment of bile did not reduce GII.3 replication, indicating a nonproteinaceous component in bile functions as an active factor. Here we show that bile acids ...
28 CitationsSource
#1Ruei-Min Lu (AS: Academia Sinica)H-Index: 5
#2Yu‐Chyi Hwang (AS: Academia Sinica)H-Index: 2
Last. Han-Chung Wu (AS: Academia Sinica)H-Index: 31
view all 7 authors...
It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved. Current antibody drugs have increasingly fewer adverse effects due to their high specificity. As a result, therapeutic antibodies have become the predominant class of new drugs developed in recent years. Over the past five years, antibodies have become the best-selling drugs in...
177 CitationsSource
Cited By0
Newest